Media headlines about Blueprint Medicines (NASDAQ:BPMC) have been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Blueprint Medicines earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 47.027600007263 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Blueprint Medicines (NASDAQ:BPMC) traded up $0.79 during mid-day trading on Friday, reaching $79.24. 158,155 shares of the company were exchanged, compared to its average volume of 417,304. The firm has a market cap of $3,364.15, a PE ratio of -23.24 and a beta of 1.29. The company has a quick ratio of 11.28, a current ratio of 11.28 and a debt-to-equity ratio of 0.02. Blueprint Medicines has a one year low of $30.98 and a one year high of $92.00.
Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.06). Blueprint Medicines had a negative return on equity of 43.11% and a negative net margin of 437.83%. The company had revenue of $8.07 million during the quarter, compared to analyst estimates of $5.35 million. During the same quarter last year, the business earned ($0.62) earnings per share. The firm’s revenue for the quarter was up 31.0% on a year-over-year basis. sell-side analysts anticipate that Blueprint Medicines will post -3.75 earnings per share for the current year.
A number of equities research analysts recently weighed in on BPMC shares. DA Davidson began coverage on shares of Blueprint Medicines in a report on Friday, September 29th. They set a “buy” rating and a $90.00 price objective for the company. BTIG Research began coverage on shares of Blueprint Medicines in a research report on Friday, September 29th. They set a “buy” rating and a $90.00 target price on the stock. Goldman Sachs Group reissued a “buy” rating and set a $79.00 target price (up previously from $64.00) on shares of Blueprint Medicines in a research report on Wednesday, September 20th. Canaccord Genuity raised their target price on shares of Blueprint Medicines from $56.00 to $66.00 and gave the company a “buy” rating in a research report on Wednesday, September 20th. Finally, Cowen reissued a “buy” rating on shares of Blueprint Medicines in a research report on Tuesday, October 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. Blueprint Medicines currently has an average rating of “Buy” and a consensus target price of $84.10.
In related news, insider Marion Dorsch sold 18,334 shares of the business’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $65.45, for a total value of $1,199,960.30. Following the completion of the transaction, the insider now directly owns 18,334 shares in the company, valued at approximately $1,199,960.30. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Anthony L. Boral sold 5,000 shares of the business’s stock in a transaction on Monday, November 6th. The shares were sold at an average price of $70.40, for a total transaction of $352,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 58,334 shares of company stock valued at $3,978,160. Company insiders own 3.40% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Blueprint Medicines (NASDAQ:BPMC) Getting Somewhat Positive Media Coverage, Study Finds” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/13/blueprint-medicines-bpmc-receiving-somewhat-positive-press-coverage-study-shows.html.
About Blueprint Medicines
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.